Health Novo Nordisk’s UBT251 Shows 19.7% Weight Loss in China Trial by Dr Natalie Singh - Health Editor February 24, 2026 by Dr Natalie Singh - Health Editor February 24, 2026 Novo Nordisk’s UBT251 Shows Promise in Obesity Treatment Following CagriSema Setback Novo Nordisk is seeking a path forward in the competitive obesity drug market following the recent failure of its … 0 FacebookTwitterPinterestEmail